Wall Street brokerages predict that Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Rating) will announce earnings of ($0.31) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Mersana Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.65) and the highest estimate coming in at ($0.09). Mersana […]
Equities research analysts expect Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Rating) to post sales of $20.01 million for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Mersana Therapeutics’ earnings, with the lowest sales estimate coming in at $10,000.00 and the highest estimate coming in at $40.00 million. Mersana Therapeutics posted sales […]
Brokerages expect Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Rating) to report earnings of ($0.31) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Mersana Therapeutics’ earnings, with estimates ranging from ($0.65) to ($0.09). Mersana Therapeutics reported earnings per share of ($0.50) during the same quarter last year, […]
Mersana Therapeutics Presents Preclinical Data Highlighting Potential of XMT-2056 and XMT-1660 in Three Posters at Virtual 2021 AACR Annual Meeting
April 10, 2021 09:00 ET | Source: Mersana Therapeutics, Inc. Mersana Therapeutics, Inc. Cambridge, Massachusetts, UNITED STATES
CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today presented preclinical data from XMT-1660, a B7-H4-targeted Dolasynthen antibody-drug conjugate (ADC), and XMT-2056, an Immunosynthen-based STING-agonist ADC at the Virtual 2021 American Association for Cancer Research Annual Meeting being held from April 10-15th.